(ORMP)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Oramed Pharmaceuticals Inc. terapevtik oqsillarni og'iz orqali yuborish texnologik platformasi bilan farmatsevtik yechimlarni tadqiq qilish va ishlab chiqish bilan shug'ullanadi. Kompaniya diabetga chalingan bemorlarni davolash uchun III fazali klinik sinovlarda bo'lgan og'iz orqali yuboriladigan insulin kapsulasi ORMD-0801ni ishlab chiqadi. Kompaniya COVID-19 va boshqa yangi koronaviruslarga qarshi og'iz orqali yuboriladigan vaktsinalarni tijoratlashtirish uchun Oravax Medical Inc. bilan litsenzion shartnomalarga ega. Oramed Pharmaceuticals Inc. 2002 yilda tashkil etilgan va Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director |
| Mr. Avraham Gabay | CFO, Treasurer & Secretary |
| Mr. Joshua Hexter | Chief Operating & Business Officer |
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-14 | 8-K | ea0272889-8k_oramed.htm |
| 2026-01-07 | 8-K | ea0271929-8k_oramed.htm |
| 2025-12-31 | 8-K | ea0271432-8k_oramed.htm |
| 2025-11-17 | 8-A12B | ea0265959-8a12b_oramed.htm |
| 2025-11-13 | 10-Q | ea0264871-10q_oramed.htm |
| 2025-10-24 | 8-K | ea0262319-8k_oramed.htm |
| 2025-10-06 | 8-K | ea0260371-8k_oramed.htm |
| 2025-08-21 | 8-K | ea0254007-8k_oramed.htm |
| 2025-08-14 | 10-Q | ea0252270-10q_oramed.htm |
| 2025-07-23 | 8-K | ea0248817-8k_oramed.htm |